Caricamento...
Sitravatinib potentiates immune checkpoint blockade in refractory cancer models
Immune checkpoint blockade has achieved significant therapeutic success for a subset of cancer patients; however, a large portion of cancer patients do not respond. Unresponsive tumors are characterized as being immunologically “cold,” indicating that these tumors lack tumor antigen-specific primed...
Salvato in:
| Pubblicato in: | JCI Insight |
|---|---|
| Autori principali: | , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
American Society for Clinical Investigation
2018
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6238734/ https://ncbi.nlm.nih.gov/pubmed/30385724 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.124184 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|